Arvinas and Pfizer turn away from Ibrance
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
The gist of GSK's move is to follow Ono
The UK company buys IRDx for $1bn.
Mersana shows that B7-H4 expression matters
The latest B7-H4 ADC shows activity only in biomarker-positive patients.
Zai Lab takes a second punt on MediLink
And, in developing ZL-6201, it wants to succeed where AbbVie disappointed.
Celcuity goes early with its Pfizer cast-off
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
Pfizer moves pivotal assets into the front line
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
MaaT shoots for EU approval
But the timeline for a US green light is less clear, and the group has a cash crisis.
Biocytogen and PTK7 remain hot
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
In vivo Car-T gains traction
Clinical expansion shows regulators getting comfortable with in vivo-generated cell therapy.
